previous year were as highlighted below ; (Unit : Million Baht) Q1/2018 Q1/2017 % Change Sales and Service Income 467 461 1 Cost of sales and Services 384 339 13 Selling and Administrative Expenses 60 70 (14
in Q2/2017. (Unit: Thousand Baht) Revenues Gross Profit Selling Admin Net(loss) profit Q2/17 222,225 80,232 19,957 22,698 (293,091)*** Q2/18 221,202 78,238 21,637 19,916 35,335 Change -1,023 -1,994
higher than the last year quarter of THB 165 million due to the strengthen in THB as compared to US dollar. There would be the material change in Q3 for the Balance Sheet structure of which expecting to
, Suriyawong, Bangrak, Bangkok 10500, Thailand. Tel. 02-634-0225 Fax 02-634-0135 www.interpharma.co.th Financial Position As at December 31 Change 2019 2018 MB MB MB % Total assets 525.87 195.47 330.40 169.03
. Financial Position As at December 31 Change 2019 2018 MB MB MB % Total assets 525.87 195.47 330.40 169.03 Total liabilities 60.13 88.48 (28.35) (32.04) Total shareholders’ equity 465.74 106.99 358.75 335.31
nearly the same, there is no significant change. Service Income In 2019, the company’s and subsidiaries’ service income was totally Baht 5.94 million, whereas none of them in 2018, increasing Baht 5.94
results for the six-month period of 2019, change of rate more than 20 percent Dear Director and Manager The Stock Exchange of Thailand According to the resolution of the Board of Directors of DOD Biotech
income (3) increased efficiency in support functions which resulted in limited increase in administrative expenses. Analysis of Financial Position Assets As of 31 December 2017, and 31 December 2018, the
Revenues and Net Profit Consolidated FS Q1/2019 Q1/2020 Change MB. % MB. % MB. % Revenue from contracts with customers 89.9 16.3% 97.1 12.7% 7.1 7.9% Interest income and dividend income 336.4 60.9% 362.8
Change 9M/2018 9M/2017 Change MB MB % MB MB % Services income from debts collection and others 77.7 60.5 28.4% 201.8 177.0 14.0% Revenues from collection of purchased accounts receivables 369.3 288.9 27.8